Crescent Biopharma develops cancer treatments, including antibody and antibody drug conjugate candidates still in clinical trials. It last closed at $13.04 on Nov 17, down 3.41% on the day. The average 12-month price target from 3 analysts is $33.00 (+153.1% from the last close), with a high of $40.00 and a low of $27.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in CBIO, 100% of them bullish and 0% bearish.
Each firm's latest rating on CBIO in the past 90 days
Average 12-month target
$33.00
▲ 153.1% upside
Based on 3 analysts who set a price target on CBIO in the past 90 days. The average target is $33.00, with a high of $40.00 and a low of $27.00, compared with the last close of $13.04.
Low $27.00Avg $33.00High $40.00
Blue marker: last close $13.04
Highest target$40.00
Average target$33.00
Lowest target$27.00
Latest rating changes
Piper SandlerMaintained
Nov 13Buy$32
HC Wainwright & Co.Target raised
Nov 13Buy$36 → $40
HC Wainwright & Co.Reiterated
Oct 19Buy$36
HC Wainwright & Co.Upgrade
Oct 6Buy$36
WedbushReiterated
Aug 27Buy$27
Date
Firm
Action
Rating
Price target
Nov 13
Piper Sandler
Maintained
Buy
$32
Nov 13
HC Wainwright & Co.
Target raised
Buy
$36 → $40
Oct 19
HC Wainwright & Co.
Reiterated
Buy
$36
Oct 6
HC Wainwright & Co.
Upgrade
Buy
$36
Aug 27
Wedbush
Reiterated
Buy
$27
Loading…
Technical Analysis
CBIO · as of the Nov 17 close · updated after every close
Downtrend
The stock is 3% below its 20 day and 11% below its 50 day average. It is 23% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the Pivot S1 at $12.72, and the nearest resistance the Pivot at $13.21.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 8.6%/day
Key levels
$27.4152 week high+110.2%
$15.99200 day average+22.6%
$15.67100 day average+20.2%
$14.5150 day average+11.3%
$13.81Swing high (Oct 21)+5.9%
$13.53Pivot R1+3.8%
$13.4920 day average+3.5%
$13.21Pivot+1.3%
$13.04Last close
$12.72Pivot S1−2.5%
$12.68Swing low (Nov 2)−2.8%
$8.7252 week low−33.1%
Indicators
RSI (14)
43.88
Middle of its range
Neutral
MACD
-0.11
Above its signal line
Bullish
Stochastic
32.6
Middle of its range
Neutral
ADX (14)
11.6
No clear trend
Williams %R
-87.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-54.4
Oversold below −100, overbought above 100
Neutral
Rate of change
−0.1%
Change over 10 sessions
Bearish
ATR (14)
$1.13
Typical daily range, 8.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 20.7%/day
Key levels
$27.4152 week high+110.2%
$15.99200 day average+22.6%
$15.67100 day average+20.2%
$14.5150 day average+11.3%
$13.81Swing high (Oct 21)+5.9%
$13.53Pivot R1+3.8%
$13.4920 day average+3.5%
$13.21Pivot+1.3%
$13.04Last close
$12.72Pivot S1−2.5%
$12.68Swing low (Nov 2)−2.8%
$8.7252 week low−33.1%
Indicators
RSI (14)
43.07
Middle of its range
Neutral
MACD
-0.93
Below its signal line
Bearish
Stochastic
17.0
Near the bottom of its range
Oversold
ADX (14)
12.5
No clear trend
Williams %R
-88.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-85.9
Oversold below −100, overbought above 100
Neutral
Rate of change
−32.8%
Change over 10 sessions
Bearish
ATR (14)
$2.70
Typical daily range, 20.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CBIO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow CBIO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CBIO is in one of them and how their past CBIO trades turned out.
Crescent Biopharma is a biotechnology company based in Waltham, Massachusetts, that develops treatments for cancer. Its lead candidate, CR-001, is an antibody designed to bind two proteins, PD-1 and VEGF, that affect how tumors grow and how the immune system responds. The company is also developing antibody drug conjugates, which are designed to deliver a toxin directly to cancer cells. Its candidates are still in clinical trials and are not yet approved for sale.